Acuitas Investments LLC Grows Stock Position in Harvard Bioscience, Inc. (NASDAQ:HBIO)

Acuitas Investments LLC increased its stake in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 24.8% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 407,343 shares of the medical instruments supplier’s stock after purchasing an additional 80,827 shares during the quarter. Acuitas Investments LLC’s holdings in Harvard Bioscience were worth $1,161,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the company. AMH Equity Ltd increased its position in shares of Harvard Bioscience by 7.5% in the first quarter. AMH Equity Ltd now owns 2,324,200 shares of the medical instruments supplier’s stock valued at $9,855,000 after buying an additional 161,307 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Harvard Bioscience by 2.4% in the 1st quarter. Vanguard Group Inc. now owns 2,152,147 shares of the medical instruments supplier’s stock valued at $9,125,000 after acquiring an additional 49,576 shares during the period. Heartland Advisors Inc. lifted its holdings in shares of Harvard Bioscience by 2.6% during the 1st quarter. Heartland Advisors Inc. now owns 889,133 shares of the medical instruments supplier’s stock valued at $3,770,000 after acquiring an additional 22,666 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Harvard Bioscience by 13.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 274,635 shares of the medical instruments supplier’s stock valued at $783,000 after purchasing an additional 31,505 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its position in shares of Harvard Bioscience by 193.9% during the second quarter. Assenagon Asset Management S.A. now owns 227,701 shares of the medical instruments supplier’s stock worth $649,000 after acquiring an additional 150,218 shares during the last quarter. Institutional investors and hedge funds own 80.87% of the company’s stock.

Insider Activity at Harvard Bioscience

In related news, CEO James W. Green bought 10,000 shares of the company’s stock in a transaction on Thursday, June 13th. The shares were purchased at an average cost of $2.91 per share, with a total value of $29,100.00. Following the completion of the transaction, the chief executive officer now directly owns 3,111,091 shares of the company’s stock, valued at $9,053,274.81. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 9.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded shares of Harvard Bioscience from a “buy” rating to a “hold” rating in a research report on Thursday, May 9th.

Harvard Bioscience Stock Down 0.7 %

Shares of NASDAQ:HBIO opened at $2.73 on Friday. The company’s fifty day moving average is $3.00 and its two-hundred day moving average is $3.50. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.94 and a current ratio of 2.05. Harvard Bioscience, Inc. has a 1-year low of $2.61 and a 1-year high of $5.56. The stock has a market capitalization of $118.56 million, a price-to-earnings ratio of -13.65 and a beta of 1.30.

Harvard Bioscience (NASDAQ:HBIO) last released its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.06). The business had revenue of $23.10 million for the quarter, compared to analyst estimates of $29.91 million. Harvard Bioscience had a negative return on equity of 2.70% and a negative net margin of 10.56%. Equities analysts anticipate that Harvard Bioscience, Inc. will post 0.11 EPS for the current year.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.